220 related articles for article (PubMed ID: 17690594)
61. [Old patients suffering from long-standing schizophrenia: clinical aspects].
Jalenques I; Rachez C; Tourtauchaux R; Cellier Y; Legrand G
Geriatr Psychol Neuropsychiatr Vieil; 2011 Sep; 9(3):345-53. PubMed ID: 21896437
[TBL] [Abstract][Full Text] [Related]
62. Drug initiatives to improve cognitive function.
Marder SR
J Clin Psychiatry; 2006; 67 Suppl 9():31-5; discussion 36-42. PubMed ID: 16965187
[TBL] [Abstract][Full Text] [Related]
63. Psychopathological long-term outcome of schizophrenia -- a review.
Lang FU; Kösters M; Lang S; Becker T; Jäger M
Acta Psychiatr Scand; 2013 Mar; 127(3):173-82. PubMed ID: 23136879
[TBL] [Abstract][Full Text] [Related]
64. [Longterm therapy of schizophrenia].
Pajonk FG; Wobrock T; Falkai P
Fortschr Neurol Psychiatr; 2005 Mar; 73(3):161-74; quiz 175-7. PubMed ID: 15747226
[No Abstract] [Full Text] [Related]
65. Understanding symptoms of schizophrenia.
Malla AK
Can J Psychiatry; 1995 Apr; 40(3 Suppl 1):S12-7. PubMed ID: 7627923
[TBL] [Abstract][Full Text] [Related]
66. [Long-term treatment and rehabilitation of schizophrenic patients].
Hofmann G; Schöny W
Wien Klin Wochenschr Suppl; 1984; 154():4-8. PubMed ID: 6151756
[TBL] [Abstract][Full Text] [Related]
67. Maintenance therapy.
Saito H; Saijo T
Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S31-4. PubMed ID: 10560895
[TBL] [Abstract][Full Text] [Related]
68. Mortality in schizophrenia.
Auquier P; Lançon C; Rouillon F; Lader M; Holmes C
Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):873-9. PubMed ID: 17058327
[TBL] [Abstract][Full Text] [Related]
69. [Current concepts of pharmacological treatment in schizophrenia].
Jarema M
Psychiatr Pol; 2002; 36(6):857-68. PubMed ID: 12725017
[TBL] [Abstract][Full Text] [Related]
70. [Long-term medication in schizophrenic psychoses].
Gaebel W
Fortschr Neurol Psychiatr; 2000 Apr; 68 Suppl 1():S26-31. PubMed ID: 10907610
[TBL] [Abstract][Full Text] [Related]
71. ["Higher outcomes"--optimizing therapy of schizophrenia].
Rüther E
Krankenpfl J; 2004; 42(5-6):151. PubMed ID: 15527215
[No Abstract] [Full Text] [Related]
72. The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals?
Möller HJ
Psychiatr Danub; 2016 Dec; 28(4):435-440. PubMed ID: 27855437
[TBL] [Abstract][Full Text] [Related]
73. Biological determinants of difficult to treat patients with schizophrenia.
Sharma T; Kerwin R
Br J Psychiatry Suppl; 1996 Dec; (31):5-9. PubMed ID: 8968649
[No Abstract] [Full Text] [Related]
74. Indications for long-term pharmacological treatment of schizophrenic syndromes.
Perris C
Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):149-58. PubMed ID: 10585
[TBL] [Abstract][Full Text] [Related]
75. [Strategies of long-term medication in schizophrenia].
Gaebel W
Fortschr Neurol Psychiatr; 2001 Sep; 69 Suppl 2():S113-9. PubMed ID: 11533861
[TBL] [Abstract][Full Text] [Related]
76. Poison or cure: meanings of medication in schizophrenia.
Rosenfield PJ
J Am Acad Psychoanal Dyn Psychiatry; 2007; 35(2):189-201. PubMed ID: 17650972
[TBL] [Abstract][Full Text] [Related]
77. [Subjective aspects of psychopharmacology in schizophrenia].
Murawiec S
Psychiatr Pol; 1999; 33(1):25-35. PubMed ID: 10786213
[TBL] [Abstract][Full Text] [Related]
78. Focus on levomepromazine.
Green B; Pettit T; Faith L; Seaton K
Curr Med Res Opin; 2004 Dec; 20(12):1877-81. PubMed ID: 15701205
[TBL] [Abstract][Full Text] [Related]
79. [CUtLASS 1 - Increasing disillusion about 2nd generation neuroleptics].
Steinert T
Psychiatr Prax; 2007 Jul; 34(5):255-7. PubMed ID: 17607643
[No Abstract] [Full Text] [Related]
80. Strategies of clinical research on neurobiological determinants of psychosis.
Helmchen H; Gaebel W
Psychiatr Dev; 1987; 5(1):51-62. PubMed ID: 2885833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
